Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor
, on female rat bladder in a partial bladder outlet obstruction model.
ICOS and partner Eli Lilly and Company are jointly developing IC351, a phosphodiesterase 5 inhibitor
for the treatment of erectile dysfunction.
In a 44 patient overseas study assessing the safety and efficacy (erectile response) of IC351 (the Company's phosphodiesterase 5 inhibitor
for the treatment of erectile dysfunction), IC351-treated patients showed significant improvement relative to placebo-treated patients in the primary endpoint (p<0.
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors
alone or in combination with [alpha]-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Treatment of phosphodiesterase 5 inhibitors
shows insufficient effectiveness in the treatment of post-prostatectomy ED and it is believed that the transplantation of stem cells cultivated on the surface of nanofibrous meshes can promote cavernous neuronal regeneration and repair erectile dysfunction.
Phosphodiesterase 5 Inhibitors
to Treat Erectile Dysfunction